An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose Homeostasis

被引:130
作者
Baggio, Laurie L. [1 ,2 ,3 ]
Huang, Qingling [1 ,2 ,3 ]
Cao, Xiemin [1 ,2 ,3 ]
Drucker, Daniel J. [1 ,2 ,3 ]
机构
[1] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Samuel Lunenfeld Res Inst, Toronto, ON, Canada
[3] Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 1L5, Canada
关键词
D O I
10.1053/j.gastro.2008.01.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis through multiple mechanisms including direct actions on the endocrine pancreas and indirect activation of central nervous system circuits regulating gastric emptying, satiety, and body weight. Because native GLP-1 is rapidly degraded, there is considerable interest in development of more potent GLP-1 receptor (GLP-1R) agonists with sustained activity; however, the extent to which much larger GLP-1R agonists will mimic some or all of the actions of smaller peptides remains uncertain. Methods: We studied the actions of CJC-1134-PC, a recombinant human serum albumin-exendin-4 conjugated protein, at the GLP-1R using heterologous cells expressing the GLP-1R in vitro and both wild-type and Glp1r(-/-) mice in vivo. Results: CJC-1134-PC activated GLP-1R-dependent signaling in baby hamster kidney-GLP-1R cells and acutely lowered blood glucose in wild-type but not in Glp1r(-/-) mice. Moreover, acute administration of CJC-1134-PC rapidly activated c-Fos expression in multiple regions of the central nervous system, acutely inhibited gastric emptying, and produced sustained inhibition of food intake in a GLP-1R-dependent manner. Furthermore, chronic daily treatment of high-fat diet-fed wild-type mice with CJC-1134-PC for 4 weeks led to improved glucose tolerance, increased levels of glucose-stimulated insulin, decreased HbA1c, and weight loss associated with decreased hepatic triglyceride content. Conclusions: These findings illustrate that a high-molecular-weight exendin-4-albumin conjugate retains the ability to mimic a full spectrum of GLP-1R-dependent actions, including activation of central nervous system circuits regulating gastric emptying, food intake, and body weight.
引用
收藏
页码:1137 / 1147
页数:11
相关论文
共 36 条
  • [1] The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
    Abbott, CR
    Monteiro, M
    Small, CJ
    Sajedi, A
    Smith, KL
    Parkinson, JRC
    Ghatei, MA
    Bloom, SR
    [J]. BRAIN RESEARCH, 2005, 1044 (01) : 127 - 131
  • [2] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
    Agerso, H
    Jensen, LB
    Elbrond, B
    Rolan, P
    Zdravkovic, M
    [J]. DIABETOLOGIA, 2002, 45 (02) : 195 - 202
  • [3] Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet
    Andrikopoulos, S
    Massa, CM
    Aston-Mourney, K
    Funkat, A
    Fam, BC
    Hull, RL
    Kahn, SE
    Proietto, J
    [J]. JOURNAL OF ENDOCRINOLOGY, 2005, 187 (01) : 45 - 53
  • [4] Characterization of the effects of pancreatic polypeptide in the regulation of energy balance
    Asakawa, A
    Inui, A
    Yuzuriha, H
    Ueno, N
    Katsuura, G
    Fujimiya, M
    Fujino, MA
    Niijima, A
    Meguid, MM
    Kasuga, M
    [J]. GASTROENTEROLOGY, 2003, 124 (05) : 1325 - 1336
  • [5] A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
    Baggio, LL
    Huang, QL
    Brown, TJ
    Drucker, DJ
    [J]. DIABETES, 2004, 53 (09) : 2492 - 2500
  • [6] Chuang VTG, 2002, PHARMACEUT RES, V19, P569
  • [7] Therapeutic strategies based on glucagon-like peptide 1
    Deacon, CF
    [J]. DIABETES, 2004, 53 (09) : 2181 - 2189
  • [8] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    DeFronzo, RA
    Ratner, RE
    Han, J
    Kim, DD
    Fineman, MS
    Baron, AD
    [J]. DIABETES CARE, 2005, 28 (05) : 1092 - 1100
  • [9] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Drucker, Daniel J.
    Nauck, Michael A.
    [J]. LANCET, 2006, 368 (9548) : 1696 - 1705
  • [10] Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis
    Drucker, DJ
    [J]. MOLECULAR ENDOCRINOLOGY, 2003, 17 (02) : 161 - 171